Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

Objective To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP‐690,550) or adalimumab monotherapy with placebo for the treatment of active rheumatoid arthritis (RA) in patients with an inadequate response to disease‐modifying antirheumatic drugs. Methods In this 24‐we...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2012-03, Vol.64 (3), p.617-629
Hauptverfasser:	Fleischmann, Roy, Cutolo, Maurizio, Genovese, Mark C., Lee, Eun Bong, Kanik, Keith S., Sadis, Seth, Connell, Carol A., Gruben, David, Krishnaswami, Sriram, Wallenstein, Gene, Wilkinson, Bethanie E., Zwillich, Samuel H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab Administration, Oral Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - therapeutic use Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Biological and medical sciences Bones, joints and connective tissue. Antiinflammatory agents Diseases of the osteoarticular system Dose-Response Relationship, Drug Double-Blind Method Drug dosages Drug Substitution Drug therapy Drug Tolerance Female Health Status Humans Immunomodulators Inflammatory joint diseases Injections, Subcutaneous Janus Kinase 3 - antagonists & inhibitors Joints - drug effects Joints - physiopathology Male Medical sciences Methotrexate - therapeutic use Middle Aged Pharmacology. Drug treatments Pilot Projects Piperidines Pyrimidines - administration & dosage Pyrimidines - therapeutic use Pyrroles - administration & dosage Pyrroles - therapeutic use Recovery of Function Rheumatism Rheumatoid arthritis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!